Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06907043 · ClinicalTrials.gov registry record · Phase 1

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

A Phase 1 study of Advanced Solid Tumors, sponsored by Eikon Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
130
Enrollment target
10
Study locations

NCT06907043 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Eikon Therapeutics. The registered enrollment target is 130 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (34% lower). The trial reports 10 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06907043, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Eikon Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
130 participants
Enrollment target
10
Study locations

Study Summary

This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer (mCRPC) and pancreatic cancer with deleterious/suspected deleterious mutations of select homologous recombination repair (HRR) genes. Condition or disease Intervention/treatment Phase Advanced Solid Tumors Drug: EIK1004 (IMP1707) Phase 1/Phase 2

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG EIK1004-001 (IMP1707-001)

Study Locations (10)

Texas

  • MD Anderson - Houston
  • NEXT Oncology - San Antonio

Colorado

  • Sarah Cannon Research Institute at HealthOne - Denver

Florida

  • Florida Cancer Center - Lake Mary

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston

Virginia

  • NEXT Virginia - Fairfax

Victoria

  • PASO Medical - Frankston

Chongqing Municipality

  • Chongqing University Cancer Hospital - Chongqing

Shandong

  • Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital) - Jinan

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2025-04-30
Est. Completion 2028-12
Phase Phase 1

Sponsor

Eikon Therapeutics

10 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06907043

The ClinicalTrials.gov registry entry for NCT06907043 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (34% lower). The listed sponsor is Eikon Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which EIK1004-001 (IMP1707-001) is the first listed.

NCT06907043 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Texas, Colorado, Florida.

Frequently Asked Questions

What is clinical trial NCT06907043 about?

NCT06907043 is a clinical study titled "A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.". This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer (mCRPC) and pancreatic cancer with deleterious/suspected deleterious mutati...

What is the current status of trial NCT06907043?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2025-04-30. Estimated completion is 2028-12.

What conditions does trial NCT06907043 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT06907043?

The interventions under investigation include: EIK1004-001 (IMP1707-001) (DRUG).

Who is sponsoring clinical trial NCT06907043?

This trial is sponsored by Eikon Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06907043 being conducted?

This trial has 10 study locations across Colorado, Florida, Massachusetts, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.